Skip to main content
    P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.48
    +0.02 (+0.05%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Pacira BioSciences, Inc. (PCRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pacira BioSciences (PCRX) has a market cap of $1.46B and an enterprise value of $1.50B. Its share count is down 9.48% from a year earlier. Its return on invested capital of 4.21% compares with a 9.88% median across 10 similar companies.

    Total Valuation

    Enterprise value is 3.20% above the market cap, as debt exceeds cash.

    Market Cap$1.46B
    Enterprise Value$1.50B
    Latest price (Nov 17, 2026)$36.48

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.02% in the quarter ended Sep 30, 2026 and shrank 7.04% a year over 2 years.

    Shares Outstanding39.86M
    Shares Change (YoY)-9.48%
    Shares Change (QoQ)+1.02%
    Share Count Growth (2Y CAGR)-7.04%

    Valuation Ratios

    Sales and book value multiples are 2.0x and 2.0x. Its year-end P/E ranged from 5.9x to 240.3x from 2016 to 2025.

    P/E Ratio20.0x
    Forward P/E12.1x
    P/S Ratio2.0x
    Forward P/S2.0x
    P/B Ratio2.0x
    P/TBV Ratio3.5x
    P/FCF Ratio8.6x
    P/OCF Ratio8.2x
    PEG Ratio2.3

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 12.2x EBITDA and 8.9x free cash flow.

    EV / Earnings39.8x
    EV / Sales2.0x
    EV / EBITDA12.2x
    EV / EBIT35.5x
    EV / FCF8.9x

    Price Statistics

    The stock is up 54.45% over 52 weeks and trades 16.22% above its 50-day average.

    Beta (1Y)0.06
    52-Week Change+54.45%
    1-Month Change+0.39%
    3-Month Change+52.00%
    6-Month Change+62.57%
    5-Year Change-30.39%
    10-Year Change+14.43%
    Total Return (1Y)+54.45%
    Total Return (3Y CAGR)+9.37%
    Total Return (5Y CAGR)-8.31%
    Return vs SPY (1Y)+38.01%
    Max Drawdown (1Y)-28.19%
    Max Drawdown (3Y)-67.02%
    Sharpe Ratio (1Y)0.80
    Correlation with SPY (1Y)0.02
    50-Day Average$31.39
    200-Day Average$25.73
    52-Week Range$18.80 to $36.67
    RSI (14 Days)82.9
    Average Volume (20 Days)1.07M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.68x current liabilities, and total debt is 0.41x shareholder equity.

    Current Ratio4.68x
    Quick Ratio3.65x
    Debt / Equity0.41x
    Debt / EBITDA2.40x
    Debt / FCF1.74x
    Interest Coverage3.01x

    Returns and Efficiency

    Return on invested capital is 4.21% over the last 12 months, against a 5-year average of 0.68%.

    Return on Equity (ROE)5.30%
    Return on Assets (ROA)3.14%
    Return on Invested Capital (ROIC)4.21%
    Return on Capital Employed (ROCE)3.94%
    ROE (5Y Average)0.58%
    ROA (5Y Average)0.15%
    ROIC (5Y Average)0.68%
    Asset Turnover0.59x
    Inventory Turnover1.20x
    Receivables Turnover5.82x
    Cash Conversion Cycle327 days

    Scores

    PCRX has an Altman Z-Score of 2.79, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score2.79
    Altman Z ZoneGrey
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $743.30M over the last 12 months is up 3.70% from the 12 months before.

    Revenue$743.30M
    Revenue Growth (YoY)+3.70%
    Gross Profit$585.19M
    Operating Income$35.78M
    Pretax Income$36.94M
    Net Income$37.73M
    EBITDA$122.58M
    EBIT$42.37M
    Reported EPS (TTM)$1.82

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 59.36% of the $1.20B in total assets.

    Cash and Equivalents$246.96M
    Total Debt$293.59M
    Net Debt$46.63M
    Net Debt Per Share$1.17
    Working Capital$464.13M
    Shareholder Equity$712.32M
    Book Value Per Share$17.87
    Tangible Book Value$419.79M
    Tangible Book Per Share$10.53
    Total Assets$1.20B
    Total Liabilities$490.32M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $7.90M of capital spending, operating cash flow left $169.00M of free cash flow.

    Operating Cash Flow$176.90M
    Capital Expenditures$7.90M
    Free Cash Flow$169.00M
    FCF Per Share$4.23
    Depreciation and Amortization$88.91M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 4.81%, against a 5-year average of 5.25%.

    Gross Margin78.73%
    Operating Margin4.81%
    Pretax Margin4.97%
    Net Margin5.08%
    EBITDA Margin16.49%
    EBIT Margin5.70%
    FCF Margin22.74%
    Gross Margin (5Y Average)77.37%
    Operating Margin (5Y Average)5.25%
    Net Margin (5Y Average)0.62%

    Growth

    Revenue fell 18.33% a year over 3 years, and EPS 2.78% a year.

    Revenue Growth (3Y CAGR)-18.33%
    Revenue Growth (5Y CAGR)+11.07%
    EPS Growth (3Y CAGR)-2.78%
    EPS Growth (5Y CAGR)+1.59%
    FCF Growth (3Y CAGR)+5.86%
    FCF Growth (5Y CAGR)+28.35%
    Operating Income Growth (3Y CAGR)-31.62%
    Book Value Per Share Growth (2Y CAGR)-1.77%
    Tangible Book Per Share Growth (2Y CAGR)+28.49%

    Revenue and profit by year

    Dividends and Yields

    PCRX does not pay a dividend. Its free cash flow yield is 11.62%.

    Earnings Yield5.00%
    FCF Yield11.62%
    Buyback Yield6.77%
    Shareholder Yield6.77%

    Peer Position

    Against 11 similar companies, PCRX has the 4th highest P/E.

    P/E Ratio20.0x vs 10.7x median
    P/S Ratio2.0x vs 2.0x median
    ROIC4.21% vs 9.88% median
    Revenue Growth (Trailing 4 Quarters, YoY)+3.70% vs +19.68% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.23% and EPS growth at 21.44% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.23%
    EPS Growth Forecast (2Y CAGR)+21.44%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PCRX

    What is PCRX's market cap?

    Pacira BioSciences has a market cap of $1.46B. Its enterprise value, which adds debt and subtracts cash, is $1.50B.

    What is PCRX's P/E ratio?

    Pacira BioSciences has a trailing P/E ratio of 20.0x and a forward P/E of 12.1x.

    How many shares of PCRX are outstanding?

    Pacira BioSciences has 39.86M shares outstanding. The count is down 9.48% from a year earlier.

    Does PCRX pay a dividend?

    No. Pacira BioSciences does not pay a dividend.

    How much debt does PCRX have?

    Pacira BioSciences has $293.59M of total debt and $246.96M of cash and equivalents, a net debt position of $46.63M.